Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)

Université Laval

$120,000.00

Prostate cancer risk: Validation and optimisation of a biomarker-integrated risk calculator within the Canadian prospective cohort BIOCaPPE (Biomarkers in Prostate Cancer: Prevention and Environment)

EF 2025-26

Résumé
Prostate cancer is the most common cancer in men and remains a leading cause of cancer-related mortality. Although the Prostate-Specific Antigen (PSA) blood test can aid in early detection, its accuracy is limited. In some cases, it may indicate the presence of cancer that would not progress or cause harm. This can lead to unnecessary stress and potentially avoidable treatments. To tackle this issue, we have developed PROSTia®, a new risk calculator powered by artificial intelligence. Unlike the PSA test alone, PROSTia® considers a wide range of factors including medical history, family background, lifestyle habits (diet, exercise, smoking, alcohol, etc.), and specific blood markers, to give a complete picture of a patient's risk and guide appropriate clinical decisions. The long-term goal of this project is to give each man a personalized estimate of his risk of developing prostate cancer in the upcoming years. To achieve this, we aim to validate and improve the PROSTia® tool by using data from a large clinical study conducted across multiple centers throughout the province of Quebec, Canada. More than 2,050 men at risk of prostate cancer have been enrolled in the study and followed for over 10 years, with extensive data on lifestyle and clinical features. By integrating new biological markers and lifestyle data to the risk calculator, we aim to enhance its accuracy in identifying who truly require closer monitoring or treatment, while minimizing unnecessary testing and interventions for others. Ultimately, this project will provide patients, their families and physicians with reliable tool to better prevent, detect and treat prostate cancer. It will also reduce healthcare costs and mitigate the negative impacts associated with overdiagnosis.
Programme
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
559454
Name
Larose Clément
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Clinical
Prcname2
DT2 (Health services and population health research) CGRS Doctoral
Projecttitle
Prostate cancer risk: Validation and optimisation of a biomarker-integrated risk calculator within the Canadian prospective cohort BIOCaPPE (Biomarkers in Prostate Cancer: Prevention and Environment)
Programtype2
Studentship Programs
Orgnameinp2
Université Laval
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Artificial Intelligence; Biomarkers; Precision Medicine; Prostate Cancer Risk; Risk Calculator; Risk Factors
Abstract
Prostate cancer is the most common cancer in men and remains a leading cause of cancer-related mortality. Although the Prostate-Specific Antigen (PSA) blood test can aid in early detection, its accuracy is limited. In some cases, it may indicate the presence of cancer that would not progress or cause harm. This can lead to unnecessary stress and potentially avoidable treatments. To tackle this issue, we have developed PROSTia®, a new risk calculator powered by artificial intelligence. Unlike the PSA test alone, PROSTia® considers a wide range of factors including medical history, family background, lifestyle habits (diet, exercise, smoking, alcohol, etc.), and specific blood markers, to give a complete picture of a patient's risk and guide appropriate clinical decisions. The long-term goal of this project is to give each man a personalized estimate of his risk of developing prostate cancer in the upcoming years. To achieve this, we aim to validate and improve the PROSTia® tool by using data from a large clinical study conducted across multiple centers throughout the province of Quebec, Canada. More than 2,050 men at risk of prostate cancer have been enrolled in the study and followed for over 10 years, with extensive data on lifestyle and clinical features. By integrating new biological markers and lifestyle data to the risk calculator, we aim to enhance its accuracy in identifying who truly require closer monitoring or treatment, while minimizing unnecessary testing and interventions for others. Ultimately, this project will provide patients, their families and physicians with reliable tool to better prevent, detect and treat prostate cancer. It will also reduce healthcare costs and mitigate the negative impacts associated with overdiagnosis.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Larose, Clément
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~